Surveillance in Barrett's oesophagus

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 6, 2006, Pages 585-588

  Thomas, Titus ^a   De Caestecker, John S ^a,b  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Barrett's oesophagus; Surveillance

Indexed keywords

ADVANCED CANCER; BARRETT ESOPHAGUS; COST EFFECTIVENESS ANALYSIS; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PRECANCER; PRIORITY JOURNAL; REVIEW;

EID: 33744478898     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200606000-00002     Document Type: Review

References (32)

1. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104:510-513.
2. Guidelines for the diagnosis and management of Barrett's columnar lined oesophagus. A report of the working party of the British Society of Gastroenterology. 2005. Available at: http://www.bsg.org.uk. Accessed: 2 February 2006.
3. Hammeteman W, Tytgat JNG, Houthoff JH, Van Den Tweel JG. Barrett's oesophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96:1249-1256.
4. Dulai SG, Shekelle GP, Jensen MD, Speigel MRB, Chen J, Oh D, et al. Dysplasia and risk of further neoplastic progression in a regional veterans administration Barrett's cohort. Am J Gastroenterol 2005; 100:775-783.
5. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's oesophagus? Gastrenterology 2000; 119:333-338.
6. Jankowski JA, Provenzale D, Moayyeddi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122:588-590.
7. Caygill CP, Watson A, Reed PI, Hill MJ. UK National Barrett's oesophagus registry (UKBOR) and the 27 participating centers. Characteristics and regional variations of patients with Barrett's oesophagus in the UK. Eur J Gastroenterol Hepatol 2003; 15:1217-1222.
8. Wright TA, Gray MR, Morris I, Gilmore TI, Ellis A, Smart LH, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996; 39:574-579.
9. Spechler JS. Endoscopic surveillance for patients with Barrett's oesophagus: does the cancer risk justify the practice? [Editorial]. Ann Intern Med 1987; 106:902-904.
10. Provenzale D, Smith C, Wong JB. Barrett's oesophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94:2043-2053.
11. Gladman L, Chapman W, Iqbal TH, Gearty GC, Cooper BT. Barrett's oesophagus: an audit of surveillance over a 17-year period. Eur J Gastroenterol Hepatol 2006; 18:271-276.
12. MacDonald CE, Wicks AC, Playford RJ. Final results from 10-year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000; 321:1252-1255.
13. Ferraris R, Bonnelli L, Conio M, Fracchia M, Lapertosa G, Aste H, et al. Incidence of adenocarcinoma in an Italian population: an endoscopic surveillance programme. Eur J Gastroenterol Hepatol 1997; 9:881-885.
14. Perry I, Harrison RF, Bryan T, Haddadin W, Taniere P, Shepherd NA, Jankowski JNZ. Optimisation of endoscopy biopsy protocol in long segment Barrett's oesophagus: evidence from 125 consecutive cases [Abstract no. 164]. Gut 2003; 52 (suppl 1):A45.
15. Panjehpour M, Overholt BF, Haydek JM, Lee SG. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol 2000; 95:2177-2184.
16. Attwood SE, Lewis CJ, Caplin S, Hemming K, Armstrong G. Argon beam coagulation as therapy for high-grade dysplasia in Barrett's oesophagus. Clin Gastroenterol Hepatol 2003; 1:258-263.
17. Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118:670-677.
18. May A, Gossner L, Pech O, Fritz A, Gunter E, Mayer G, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and long-term results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 14:1085-1091.
19. Mandal A, Playford RJ, Wicks AC. Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. Aliment Pharmacol Ther 2003; 17:1319-1324.
20. Thomas T, Nair P, Dronfield MW, Mayberry JF. Management of low- and high-grade dysplasia in inflammatory bowel disease: a gastroenterologists' perspective and current practice in the UK. Eur J Gastroenterol Hepatol 2005; 17:1317-1324.
21. Stokamer CL, Tenner CT, Chaudhuri J, Vazquez E, Bini EJ. Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing. J Gen Intern Med 2005; 20:278-282.
22. Murray L, Watson P, Johnston B, Sloan J, Mainie IML. Risk of adenocarcinoma in Barrett's oesophagus: a population based study. BMJ 2003; 327:534-535.
23. Solaymani-Dodaran M, Logan RFA, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastrooesophageal refflux. Gut 2004; 53:1070-1074.
24. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99:1877-1883.
25. Hillman LC, Chiragakis L, Sanbolt B, Kaye GL, Clarke AC. Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180:387-391.
26. Corley DA, Kerlikowske K, Verma R, Buffler PO. Protective association of aspirin/NSAIDs and oesophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124:47-56.
27. Conio M, Blanchi S, Lapertosa G, Ferraris R, Sablich R, Marchi S, et al. Long-term endoscopic surveillance of patients with Barrett's oesophagus. Incidence of dysplasia and adenocarcinoma. A prospective study. Am J Gastroenterol 2003; 98:1931-1939.
28. Thomas T, Richards CJ, de Caestekar J, Robinson RJ. Management of high-grade dysplasia in Barrett's oesophagus: 10-year retrospective review. Aliment Pharmacol Ther 2005; 21:747-755.
29. Enaganti SK, Moayyedi P, Jankowski J. Mortality risk factors and co-morbidity in patients with Barrett's metaplasia [Abstract no. 38]. Gut 2004; 53 (suppl 3):A62.
30. Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in oesophageal carcinoma. Am J Gastroenterol 2002; 97:1319-1327.
31. Streitz JM, Andrews CW, Ellis FH. Endoscopic surveillance of Barrett's esophagus: does it help? J Thorac Cardiovasc Surg 1993; 105:383-388.
32. Van Sandick JW, van Lanschot JJB, Kuiken BW, Tytgat GNJ, Offerhaus GJA, Obetap H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43:212-222.